Antiarrhythmic Drug Dosing in Children—Review of the Literature

Antiarrhythmic drugs represent a mainstay of pediatric arrhythmia treatment. However, official guidelines and consensus documents on this topic remain scarce. There are rather uniform recommendations for some medications (including adenosine, amiodarone, and esmolol), while there are only very broad dosage recommendations for others (such as sotalol or digoxin). To prevent potential uncertainties and even mistakes with regard to dosing, we summarized the published dosage recommendations for antiarrhythmic drugs in children. Because of the wide variations in availability, regulatory approval, and experience, we encourage centers to develop their own specific protocols for pediatric antiarrhythmic drug therapy.

[1]  I. Sigfusdottir,et al.  Effect of the COVID-19 pandemic on adolescent mental health and substance use up to March, 2022, in Iceland: a repeated, cross-sectional, population-based study , 2023, The Lancet Child & Adolescent Health.

[2]  M. van Veen,et al.  Adverse effect of lockdowns during the COVID-19 pandemic: increased incidence of pediatric crisis admissions due to eating disorders and adolescent intoxications , 2023, European Journal of Pediatrics.

[3]  Dirk G. Wilson,et al.  Flecainide administration in children: dosage, drug levels, and clinical effect. , 2022, Cardiology in the young.

[4]  M. Silka,et al.  Ectopic Atrial Tachycardia in Infants Following Congenital Heart Disease Surgery , 2022, Pediatric Cardiology.

[5]  A. Amodeo,et al.  Heart rate reduction as a marker to optimize carvedilol treatment and enhance myocardial recovery in pediatric dilated cardiomyopathy , 2022, Frontiers in Physiology.

[6]  S. Udupa,et al.  Ivabradine in the Management of Pediatric Arrhythmias. , 2022, The Canadian journal of cardiology.

[7]  F. Kipfmueller,et al.  Heart rate control with landiolol hydrochloride in infants with ventricular dysfunction and pulmonary hypertension , 2022, ESC heart failure.

[8]  C. Fraser,et al.  Routine Perioperative Esmolol After Infant Tetralogy of Fallot Repair: Single-Center Retrospective Study of Hemodynamics , 2022, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[9]  E. Velázquez-Rodríguez,et al.  Idiopathic left fascicular ventricular tachycardia in children and adolescents. , 2022, Boletin medico del Hospital Infantil de Mexico.

[10]  P. Postema,et al.  Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review , 2022, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  H. Horigome,et al.  Control of Heart Rate in Infant and Child Tachyarrhythmia With Reduced Cardiac Function Using Landiolol (HEARTFUL) - Results of a Prospective, Multicenter, Uncontrolled Clinical Study. , 2022, Circulation journal : official journal of the Japanese Circulation Society.

[12]  F. Drago,et al.  Atrial Flutter in Pediatric Patients. , 2022, Cardiac electrophysiology clinics.

[13]  Y. Hua,et al.  Efficacy and Safety of Various First-Line Therapeutic Strategies for Fetal Tachycardias: A Network Meta-Analysis and Systematic Review , 2022, Frontiers in Pharmacology.

[14]  Young Tae Lim,et al.  Effective Control of Supraventricular Tachycardia in Neonates May Requires Combination Pharmacologic Therapy , 2022, Journal of clinical medicine.

[15]  J. Saul,et al.  IV Sotalol Use in Pediatric and Congenital Heart Patients: A Multicenter Registry Study , 2022, Journal of the American Heart Association.

[16]  M. Ciabattini,et al.  Real-World Use of Carvedilol in Children With Dilated Cardiomyopathy: Long-Term Effect on Survival and Ventricular Function , 2022, Frontiers in Pediatrics.

[17]  G. Utine,et al.  Efficacy of flecainide in bidirectional ventricular tachycardia and tachycardia-induced cardiomyopathy with Andersen-Tawil syndrome. , 2022, European journal of medical genetics.

[18]  S. Priori,et al.  Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers. , 2022, JAMA cardiology.

[19]  M. McManus,et al.  Supraventricular Tachycardia in Infants With Congenital Diaphragmatic Hernia: Prevalence, Associations, and Outcomes. , 2022, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[20]  R. Weber,et al.  Antiarrhythmic Medication in Neonates and Infants with Supraventricular Tachycardia , 2022, Pediatric Cardiology.

[21]  Gretchen Hackett,et al.  Use of ivabradine in a critically ill pediatric patient with recalcitrant ectopic atrial tachycardia and complex congenital heart disease , 2022, HeartRhythm case reports.

[22]  R. Crowe,et al.  Pediatric Bradycardia Is Undertreated in the Prehospital Setting: A Retrospective Multi-Agency Analysis , 2021, Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors.

[23]  J. Skinner,et al.  An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia , 2021, Circulation.

[24]  P. Kannankeril,et al.  Sotalol vs Amiodarone for Postoperative Junctional Ectopic Tachycardia: Citius, Altius, Fortius? , 2021, Heart Rhythm.

[25]  V. Tipo,et al.  Ivabradine–Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review , 2021, Pediatric reports.

[26]  M. Tzatzarakis,et al.  Mexiletine Treatment for Neonatal LQT3 Syndrome: Case Report and Literature Review , 2021, Frontiers in Pediatrics.

[27]  Bernard Abi-Saleh,et al.  Ivabradine: A Potential Therapeutic for Children With Refractory SVT , 2021, Frontiers in Cardiovascular Medicine.

[28]  L. Sacconi,et al.  The HCN channel as a pharmacological target: Why, where, and how to block it. , 2021, Progress in biophysics and molecular biology.

[29]  G. Kaiafa,et al.  Propafenone Poisoning of a Female Adolescent After a Suicide Attempt , 2021, Cureus.

[30]  A. Kardos,et al.  Supraventricular tachycardias in neonates and infants: factors associated with fatal or near-fatal outcome , 2021, European Journal of Pediatrics.

[31]  S. Nemoto,et al.  Safety and Efficacy of Landiolol Hydrochloride in Children with Tachyarrhythmia of Various Etiologies , 2021, Pediatric Cardiology.

[32]  P. Kahr,et al.  “Second line medications” for supraventricular arrhythmias in children: In‐hospital efficacy and adverse events during treatment initiation of sotalol and flecainide , 2021, Journal of cardiovascular electrophysiology.

[33]  V. Probst,et al.  Dose response to nadolol in congenital Long QT Syndrome. , 2021, Heart rhythm.

[34]  F. Hoffmann,et al.  European Resuscitation Council Guidelines 2021: Paediatric Life Support. , 2021, Resuscitation.

[35]  S. Favilli,et al.  Supraventricular tachycardias in the first year of life: what is the best pharmacological treatment? 24 years of experience in a single centre , 2021, BMC Cardiovascular Disorders.

[36]  S. Kurath-Koller,et al.  Holiday heart syndrome: an upcoming tachyarrhythmia in today's youth? , 2021, Cardiology in the young.

[37]  Y. Liao,et al.  A case report of an infant after episodes of paroxysmal supraventricular tachycardia with left ventricular thrombosis and cerebral infarction. , 2021, Annals of palliative medicine.

[38]  N. Blom,et al.  The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study , 2021, Pediatric Cardiology.

[39]  D. Choi,et al.  Ventricular Tachycardia in Association with Propafenone Overdose. , 2021, Acta Cardiologica Sinica.

[40]  H. Kafalı,et al.  Early postoperative arrhythmias in patients undergoing congenital heart surgery , 2021, Turk gogus kalp damar cerrahisi dergisi.

[41]  G. la Marca,et al.  Incessant Automatic Atrial Tachycardia in a Neonate Successfully Treated with Nadolol and Closely Spaced Doses of Flecainide: A Case Report , 2020, Pediatric reports.

[42]  M. Hazinski,et al.  Pediatric Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. , 2020, Circulation.

[43]  F. Morgado,et al.  Fascicular tachycardia in a child: striking features that improve emergency management , 2020, BMJ Case Reports.

[44]  A. Sabate-Rotes,et al.  Flecainide intoxication in pediatric patients with supraventricular tachycardia , 2020, Annals of pediatric cardiology.

[45]  O. Aljohani,et al.  Intravenous Sotalol in the Young: Safe and Effective Treatment With Standardized Protocols. , 2020, JACC. Clinical electrophysiology.

[46]  D. Roden,et al.  Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[47]  G. Dukic,et al.  European , 2020, Definitions.

[48]  E. Gaies,et al.  Digoxin therapeutic drug monitoring: age influence and adverse events. , 2020, La Tunisie medicale.

[49]  A. Lodha,et al.  Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis , 2019, Journal of Perinatology.

[50]  F. Furlanello,et al.  Quinidine-A legacy within the modern era of antiarrhythmic therapy. , 2019, Pharmacological research.

[51]  M. Silka,et al.  A comparison of oral flecainide and amiodarone for the treatment of recurrent supraventricular tachycardia in children , 2019, Pacing and clinical electrophysiology : PACE.

[52]  J. Skinner,et al.  Fascicular tachycardia in infancy and the use of verapamil: a case series and literature review , 2019, Archives of Disease in Childhood.

[53]  L. Bolognese,et al.  Brugada Syndrome in the Young and in the Adult: A Tale of 2 Diseases? , 2019, Journal of the American College of Cardiology.

[54]  M. Pellegrino,et al.  Digoxin‐specific Fab and therapeutic plasma exchange for digitalis intoxication and renal failure , 2019, The American journal of emergency medicine.

[55]  Gareth D. K. Matthews,et al.  Quinidine Rebooted: Contemporary Approaches to Multichannel Blockade. , 2019, JACC. Clinical electrophysiology.

[56]  A. Davis,et al.  An Update on the Diagnosis and Management of Catecholaminergic Polymorphic Ventricular Tachycardia. , 2019, Heart, lung & circulation.

[57]  J. Moak Has intravenous sotalol come of age as an alternative treatment for arrhythmias in the young heart? , 2018, Heart rhythm.

[58]  V. Tuzcu,et al.  Can flecainide totally eliminate bidirectional ventricular tachycardia in pediatric patients with Andersen-Tawil syndrome? , 2018, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[59]  C. Rusin,et al.  Early experience with intravenous sotalol in children with and without congenital heart disease. , 2018, Heart rhythm.

[60]  A. Thiagalingam,et al.  The Use of Intravenous Sotalol in Cardiac Arrhythmias. , 2018, Heart, lung & circulation.

[61]  M. Nakayashiro,et al.  Combined flecainide and sotalol therapy for multifocal atrial tachycardia in cardio‐facio‐cutaneous syndrome , 2018, Pediatrics international : official journal of the Japan Pediatric Society.

[62]  L. Liberman,et al.  Advanced Heart Block in Children with Lyme Disease , 2018, Pediatric Cardiology.

[63]  Lin Wu,et al.  Modernized Classification of Cardiac Antiarrhythmic Drugs , 2018, Circulation.

[64]  L. Szydlowski,et al.  A simplified approach for evaluating sustained slow pathway conduction for diagnosis and treatment of atrioventricular nodal reentry tachycardia in children and adults. , 2018, Advances in medical sciences.

[65]  C. McMahon,et al.  Successful Treatment of Refractory Cardiac Arrest With β-Blockade and Extracorporeal Life Support in a Pediatric Patient With Catecholaminergic Polymorphic Ventricular Tachycardia: A Case Report. , 2018, A&A practice.

[66]  Bryan J. Mathis,et al.  Landiolol Hydrochloride Rapidly Controls Junctional Ectopic Tachycardia After Pediatric Heart Surgery , 2018, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[67]  Jeffrey J. Kim,et al.  Intravenous sotalol for the management of postoperative junctional ectopic tachycardia , 2018, HeartRhythm case reports.

[68]  J. Walline,et al.  Full recovery after prolonged resuscitation from cardiac arrest due to propafenone intoxication , 2018, Medicine.

[69]  E. Ozturk,et al.  Sustained tachyarrhythmia in children younger than 1 year of age: Six year single‐center experience , 2018, Pediatrics international : official journal of the Japan Pediatric Society.

[70]  P. Brugada Short QT Syndrome and Hydroquinidine: Rare Diseases and Unavailable Drugs. , 2017, Journal of the American College of Cardiology.

[71]  K. Takigiku,et al.  Study design for control of HEART rate in inFant and child tachyarrhythmia with heart failure Using Landiolol (HEARTFUL): A prospective, multicenter, uncontrolled clinical trial. , 2017, Journal of cardiology.

[72]  H. Ge,et al.  Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia , 2017, Pediatric Cardiology.

[73]  R. Collins,et al.  Propranolol Versus Digoxin in the Neonate for Supraventricular Tachycardia (from the Pediatric Health Information System). , 2017, The American journal of cardiology.

[74]  Zaixing Yang,et al.  Successful treatment of propafenone-induced cardiac arrest by calcium gluconate. , 2017, The American journal of emergency medicine.

[75]  D. Bradley,et al.  Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children , 2017, Pediatric Cardiology.

[76]  D. Atkins,et al.  Amiodarone Versus Lidocaine for Pediatric Cardiac Arrest Due to Ventricular Arrhythmias: A Systematic Review , 2017, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[77]  J. Skinner,et al.  Update on the Diagnosis and Management of Familial Long QT Syndrome. , 2016, Heart, lung & circulation.

[78]  P. Brugada,et al.  Brugada syndrome in the paediatric population: a comprehensive approach to clinical manifestations, diagnosis, and management , 2016, Cardiology in the Young.

[79]  N. Buckley,et al.  Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1) , 2016, Clinical toxicology.

[80]  T. Knilans,et al.  Variation in Antiarrhythmic Management of Infants Hospitalized with Supraventricular Tachycardia: A Multi-Institutional Analysis , 2016, Pediatric Cardiology.

[81]  S. Priori,et al.  Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3 , 2016, Journal of the American College of Cardiology.

[82]  Loretta Fala Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure. , 2016, American health & drug benefits.

[83]  W. Shimizu,et al.  Pronounced Shortening of QT Interval With Mexiletine Infusion Test in Patients With Type 3 Congenital Long QT Syndrome. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[84]  F. Bosch,et al.  Case Report: Hemodynamic Instability Following Severe Metoprolol and Imipramine Intoxication Successfully Treated With Intravenous Fat Emulsion , 2016, American journal of therapeutics.

[85]  J. Lerman,et al.  Do small doses of atropine (<0.1 mg) cause bradycardia in young children? , 2015, Archives of Disease in Childhood.

[86]  E. Karakoç,et al.  Role of intravenous lipid emulsions in the management of calcium channel blocker and β-blocker overdose: 3 years experience of a university hospital , 2015, Postgraduate medicine.

[87]  T. Potpara,et al.  How are arrhythmias managed in the paediatric population in Europe? Results of the European Heart Rhythm survey. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[88]  A. Moss,et al.  Efficacy of different beta-blockers in the treatment of long QT syndrome. , 2014, Journal of the American College of Cardiology.

[89]  A. M. Herskind,et al.  [Digoxin intoxication in an infant because of confusion of bottles of magistral preparations of medicine]. , 2014, Ugeskrift for laeger.

[90]  P. Kubuš,et al.  Electrophysiologic Profile and Results of Invasive Risk Stratification in Asymptomatic Children and Adolescents With the Wolff–Parkinson–White Electrocardiographic Pattern , 2014, Circulation. Arrhythmia and electrophysiology.

[91]  Jeffrey J. Kim,et al.  Race Contributes to Beta-Blocker Efficacy in Pediatric Patients With Arrhythmias , 2014, Pediatric Cardiology.

[92]  R. Berg,et al.  Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. , 2014, Resuscitation.

[93]  S. Poelzing,et al.  Combined inhibition of Na⁺ and Ca²⁺ channels: a novel paradigm for the treatment of incessant ventricular arrhythmias in Andersen-Tawil syndrome. , 2014, Heart rhythm.

[94]  P. Brugada,et al.  The challenges of performing ajmaline challenge in children with suspected Brugada syndrome , 2014, Open Heart.

[95]  B. Meibohm,et al.  Pharmacokinetics of intravenous amiodarone in children , 2013, Archives of Disease in Childhood.

[96]  É. Marijon,et al.  Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[97]  F. Vernuccio,et al.  Role of Bisoprolol in Patients with Long QT Syndrome , 2013, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[98]  M. Peters,et al.  The Effect of Atropine on Rhythm and Conduction Disturbances During 322 Critical Care Intubations* , 2013, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[99]  M. Dick,et al.  Verapamil in Infants: An Exaggerated Fear? , 2013, Pediatric Cardiology.

[100]  İ. Ece,et al.  Effects of carvedilol therapy on cardiac autonomic control, QT dispersion, and ventricular arrhythmias in children with dilated cardiomyopathy , 2013, Medical science monitor : international medical journal of experimental and clinical research.

[101]  D. Wiest,et al.  Clinical Pharmacokinetics and Therapeutic Efficacy of Esmolol , 2012, Clinical Pharmacokinetics.

[102]  R. Hauer,et al.  Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. , 2012, Journal of the American College of Cardiology.

[103]  A. M. Sheikh,et al.  Optimal dose of adenosine effective for supraventricular tachycardia in children. , 2012, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[104]  P. Brugada,et al.  Ajmaline Challenge in Young Individuals with Suspected Brugada Syndrome , 2011, Pacing and clinical electrophysiology : PACE.

[105]  K. Hill European Resuscitation Council Guidelines (2010) , 2011 .

[106]  J. Saul,et al.  The Pharmacokinetics of Esmolol in Pediatric Subjects with Supraventricular Arrhythmias , 2006, Pediatric Cardiology.

[107]  J. Triedman,et al.  Intravenous Amiodarone for Incessant Tachyarrhythmias in Children: A Randomized, Double-Blind, Antiarrhythmic Drug Trial , 2005, Circulation.

[108]  S. Etheridge,et al.  QT dispersion after beta-blocker therapy (carvedilol or metoprolol) in children with heart failure. , 2003, The American journal of cardiology.

[109]  C. Narasimhan,et al.  Refractory adenosine-sensitive congenital His bundle tachycardia: response to calcium-channel blockers. , 2003, Indian heart journal.

[110]  R. Pass,et al.  Continuous intravenous diltiazem infusion for short-term ventricular rate control in children. , 2000, The American journal of cardiology.

[111]  W. Allan,et al.  Long QT Syndrome , 1998, Pediatrics.

[112]  Y. Hirota,et al.  Effect of beta-blocker treatment in dilated cardiomyopathy with bradyarrhythmias. , 1998, Japanese circulation journal.

[113]  A. Garson,et al.  Long-term follow-up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects. , 1990, Journal of the American College of Cardiology.

[114]  N. Mostow,et al.  A general overview of amiodarone toxicity: its prevention, detection, and management. , 1989, Progress in cardiovascular diseases.

[115]  H. Fujino,et al.  [Electrophysiologic effects of calcium channel blockers on supraventricular tachycardia in children]. , 1989, Journal of cardiology.

[116]  S. Etheridge,et al.  A personalized approach to long QT syndrome , 2019, Current opinion in cardiology.

[117]  M. Gold,et al.  Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? , 2017, Heart rhythm.

[118]  Amy N. McCammond,et al.  Belhassen tachycardia in a 19-month-old child. , 2015, The Journal of pediatrics.

[119]  M. Romanò Inherited Cardiac Arrhythmias , 2015 .

[120]  Karly P Garnock-jones Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. , 2012, Drugs.

[121]  T. Matsumura,et al.  Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. , 2010, Internal medicine.

[122]  I. Ostman-Smith Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. , 2010, Fundamental & clinical pharmacology.